AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18832884 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant native HIV-1 Tat protein vaccine
Number of subjects: 0
Study 17060350 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary change intervention
Number of subjects: 0
Study 17060350 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 15147494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive heading during imagined locomotion
Number of subjects: 0
Study 15147494 — intervention group
Group type: COMPARATOR
Intervention: Perceived heading during imagined locomotion
Number of subjects: 0
Study 10934807 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (BiPAP) via nasal or facial mask
Number of subjects: 12
Study 10934807 — intervention group
Group type: EXPERIMENTAL
Intervention: PLV‐100 via nasal or facial mask
Number of subjects: 12
Study 9059204 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal wall elevation (AWE)
Number of subjects: 20
Study 9059204 — intervention group
Group type: COMPARATOR
Intervention: Carbon dioxide pneumoperitoneum (PN)
Number of subjects: 20
Study 7908147 — intervention group
Group type: EXPERIMENTAL
Intervention: Parlodel (bromocriptine) fast titration (15 mg/day for 3 weeks)
Number of subjects: 153
Study 7908147 — intervention group
Group type: COMPARATOR
Intervention: Parlodel (bromocriptine) slow titration (15 mg/day for 5 weeks)
Number of subjects: 153
Study 3593985 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (T) alone or T in combination with medroxyprogesterone acetate, diethylstilbestrol, halotestin, or aminoglutethimide
Number of subjects: 465
Study 28380705 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Attention Training Program (IATP)
Number of subjects: 93
Study 28380705 — intervention group
Group type: COMPARATOR
Intervention: Health-related education program (active control group)
Number of subjects: 93
Study 26945956 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic fovea landmark technique
Number of subjects: 0
Study 26945956 — intervention group
Group type: COMPARATOR
Intervention: C-arm technique
Number of subjects: 0
Study 24708917 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (60 μg/d, as Se-enriched yeast)
Number of subjects: 230
Study 24708917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 22291058 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 0
Study 20555331 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg day(-1) valsartan
Number of subjects: 181
Study 20555331 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg day(-1) valsartan
Number of subjects: 181
Study 18525061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 25) received an information sheet on coping-promoting talk.
Number of subjects: 50
Study 18525061 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25) received standard care.
Number of subjects: 50
Study 16759447 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) including Salvia miltiorrhiza, Acanthopanax senticosus, Ginkgo biloba, Pueraria lobata, Liguisticum chuanxiong, cow bezoar, Diospyros kaki, Gynostemma pentaphyllum
Number of subjects: 0
Study 16759447 — intervention group
Group type: COMPARATOR
Intervention: Calcium antagonists
Number of subjects: 0
Study 12627988 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal budesonide 128 microg twice daily
Number of subjects: 0
Study 12627988 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal budesonide 128 microg twice daily after polypectomy
Number of subjects: 0
Study 10356887 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve YIT4064, 50 mg daily for 28 days
Number of subjects: 19
Study 10356887 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19
Study 10356887 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve YIT4064
Number of subjects: 19
Study 8910175 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hemodilution (Hct 31%)
Number of subjects: 20
Study 8910175 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hemodilution (Hct 23%)
Number of subjects: 20
Study 8910175 — intervention group
Group type: COMPARATOR
Intervention: Control (no hemodilution)
Number of subjects: 20
Study 2065844 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose cisplatin (50 mg/m2) with short treatment regimen (6 months)
Number of subjects: 60
Study 2065844 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose cisplatin (50 mg/m2) with extended treatment regimen (12 months)
Number of subjects: 60
Study 2065844 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose cisplatin (50 mg/m2) with treatment in blocks (intervening months without cisplatin)
Number of subjects: 60
Study 2065844 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose cisplatin (100 mg/m2) with short treatment regimen (6 months)
Number of subjects: 60
Study 2065844 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose cisplatin (100 mg/m2) with extended treatment regimen (12 months)
Number of subjects: 60
Study 2065844 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose cisplatin (100 mg/m2) with treatment in blocks (intervening months without cisplatin)
Number of subjects: 60
Study 6359947 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 33
Study 6359947 — intervention group
Group type: COMPARATOR
Intervention: ZEEP
Number of subjects: 33
Study 30389899 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (ET)
Number of subjects: 0
Study 29666026 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with chemotherapy
Number of subjects: 0
Study 29666026 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitors (nivolumab, pembrolizumab, cemiplimab)
Number of subjects: 0
Study 27682034 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg intravenous)
Number of subjects: 2013
Study 27682034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2013
Study 24492452 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction of the elbow flexor muscles
Number of subjects: 15
Study 24492452 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest
Number of subjects: 15
Study 22119935 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa (200 mg) / benserazide (50 mg)
Number of subjects: 42
Study 22119935 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 20713668 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg peramivir
Number of subjects: 300
Study 20713668 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg peramivir
Number of subjects: 300
Study 20713668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 17555171 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert Condensable (Jeneric/Pentron)
Number of subjects: 50
Study 17555171 — intervention group
Group type: EXPERIMENTAL
Intervention: SureFil (Dentsply/Caulk)
Number of subjects: 50
Study 15880313 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose
Number of subjects: 142
Study 15880313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 12084163 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-removed platelets
Number of subjects: 129
Study 12084163 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood-derived prestorage WBC-reduced platelets
Number of subjects: 129
Study 12084163 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestorage WBC-reduced apheresis platelets
Number of subjects: 129
Study 12084163 — intervention group
Group type: COMPARATOR
Intervention: Overall frequency of reactions
Number of subjects: 129
Study 9863850 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback‐assisted behavioral treatment
Number of subjects: 197
Study 9863850 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment (oxybutynin chloride, 2.5 mg daily to 5.0 mg 3 times daily)
Number of subjects: 197
Study 9863850 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 197
Study 8721904 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin in addition to isoniazid, pyrazinamide and ethambutol
Number of subjects: 180
Study 8721904 — intervention group
Group type: COMPARATOR
Intervention: No rifampicin
Number of subjects: 180
Study 8721904 — intervention group
Group type: EXPERIMENTAL
Intervention: All four drugs (rifampicin, isoniazid, pyrazinamide, ethambutol) for younger patients
Number of subjects: 180
Study 8721904 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mean concentrations of hydrazine, rifampicin and pyrazinamide
Number of subjects: 180
Study 1694593 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (2 inhalations every 5 hours)
Number of subjects: 6
Study 1694593 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 inhalations every 5 hours)
Number of subjects: 6
Study 399315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethynyl oestradiol‐50 micron/day
Number of subjects: 49
Study 399315 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel‐250 micron/day
Number of subjects: 49
Study 399315 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordial (combination of ethynyl oestradiol and levonorgestrel)
Number of subjects: 49
Study 399315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31272334 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention video only
Number of subjects: 294
Study 31272334 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention video with discussion
Number of subjects: 294
Study 31272334 — intervention group
Group type: COMPARATOR
Intervention: Attentional control video
Number of subjects: 294
Study 31272334 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention video (both conditions)
Number of subjects: 294
Study 28972045 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative ECF chemotherapy
Number of subjects: 456
Study 28972045 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 456
Study 25185211 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 280
Study 25185211 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy (BMT)
Number of subjects: 280
Study 24628884 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Monitoring (TM; N=83)
Number of subjects: 252
Study 24628884 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Monitoring and Brief Counseling (TMC; N=83)
Number of subjects: 252
Study 24628884 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (Control)
Number of subjects: 252
Study 22873758 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections of botulinum toxin A (BoNT‐A) combined with standard therapy
Number of subjects: 40
Study 22873758 — intervention group
Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 40
Study 19387391 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated Wingate test 1 (WinD1)
Number of subjects: 7
Study 19387391 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated Wingate test 2 (WinD2)
Number of subjects: 7
Study 19387391 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated Wingate test 3 (WinD3)
Number of subjects: 7
Study 17690191 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypobaric hypoxia (IHE, 3 h/day, 5 days/wk at 4,000‐5,500 m)
Number of subjects: 23
Study 17690191 — intervention group
Group type: COMPARATOR
Intervention: Normobaric normoxia (Control group)
Number of subjects: 23
Study 17690191 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypobaric hypoxia (IHE) for swimmers
Number of subjects: 23
Study 15764114 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiphora patients
Number of subjects: 96
Study 15764114 — intervention group
Group type: COMPARATOR
Intervention: Second-eye cataract patients
Number of subjects: 96
Study 12090633 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthogonal Astigmatism Test (OAT)
Number of subjects: 50
Study 12090633 — intervention group
Group type: COMPARATOR
Intervention: Jackson Crossed-Cylinder (JCC)
Number of subjects: 50
Study 12090633 — intervention group
Group type: COMPARATOR
Intervention: Raubitschek Arrow (RA)
Number of subjects: 50
Study 12090633 — intervention group
Group type: COMPARATOR
Intervention: Fan and Block (FB)
Number of subjects: 50
Study 9839623 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase as an additive to chemotherapy and radiation therapy
Number of subjects: 0
Study 9839623 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and radiation therapy without hyaluronidase
Number of subjects: 0
Study 7983236 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg dose of loracarbef
Number of subjects: 20
Study 7983236 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg dose of loracarbef
Number of subjects: 20
Study 7983236 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg dose of loracarbef (women)
Number of subjects: 20
Study 7983236 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg dose of loracarbef (women)
Number of subjects: 20
Study 7983236 — intervention group
Group type: EXPERIMENTAL
Intervention: loracarbef
Number of subjects: 20
Study 7983236 — intervention group
Group type: EXPERIMENTAL
Intervention: loracarbef (400 mg dose)
Number of subjects: 20
Study 2499588 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU hCG
Number of subjects: 12
Study 2499588 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 31429629 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic gel containing 3%(w/w)-TTO
Number of subjects: 49
Study 31429629 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced gel containing 3%(w/w)-TTO plus essential oils and vitamins
Number of subjects: 49
Study 29560955 — intervention group
Group type: EXPERIMENTAL
Intervention: Early operative treatment (12‐hour medication)
Number of subjects: 703
Study 29560955 — intervention group
Group type: COMPARATOR
Intervention: Long‐term conservative treatment (48 hours)
Number of subjects: 703
Study 27075843 — intervention group
Group type: EXPERIMENTAL
Intervention: Household and personal cleaning products (microbicides triclosan and triclocarban)
Number of subjects: 158
Study 27075843 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly surveys
Number of subjects: 158
Study 22961838 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO (guided self-help intervention for carers)
Number of subjects: 0
Study 22961838 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 0
Study 20942668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab (10, 25, 50, 100, or 200 μg/kg)
Number of subjects: 450
Study 20942668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 20942668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 450
Study 18219181 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene plus Alfacalcidol (Group A)
Number of subjects: 60
Study 18219181 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene alone (Group B)
Number of subjects: 60
Study 16845627 — intervention group
Group type: EXPERIMENTAL
Intervention: Aventis Pasteur smallpox vaccine
Number of subjects: 74
Study 16845627 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 74
Study 12600796 — intervention group
Group type: COMPARATOR
Intervention: PGE(2) (3, 6, and 12 nmol/ml)
Number of subjects: 36
Study 12600796 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP (9000, 18,000, and 36,000 nmol/ml)
Number of subjects: 36
Study 12600796 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Bk (92 nmol), 5‐HT (156 nmol), His (140 nmol), and PGE(2) (1.95 nmol)
Number of subjects: 36
Study 11672513 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + IFN (COPP: cyclophosphamide, vincristine, prednisone, procarbazine)
Number of subjects: 55
Study 11672513 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (control group)
Number of subjects: 55
Study 9097896 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 11
Study 9097896 — intervention group
Group type: COMPARATOR
Intervention: Conventional neuroleptics
Number of subjects: 11
Study 7989949 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interleukin-2 (IL-2) (720,000 IU/kg) every 8 hours
Number of subjects: 199
Study 7989949 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IL-2
Number of subjects: 199
Study 3068855 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil (1.2 mg/kg) and dapsone (1.2 or 2.4 mg/kg)
Number of subjects: 48
Study 3068855 — intervention group
Group type: COMPARATOR
Intervention: Pyrimethamine (1.2 mg/kg) and sulfadoxine (24 mg/kg)
Number of subjects: 48
Study 29155186 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MRI-targeted and systematic biopsy
Number of subjects: 459
Study 28133919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin (125 μg intravitreal injection)
Number of subjects: 652
Study 28133919 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravitreal injection)
Number of subjects: 652
Study 25976525 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid food introduction before 4 months of age
Number of subjects: 149
Study 25976525 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid food introduction after 6 months of age
Number of subjects: 149
Study 25976525 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of introduction of hyperallergenic foods
Number of subjects: 149
Study 25976525 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian race
Number of subjects: 149
Study 25976525 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal history of food allergy
Number of subjects: 149
Study 22214282 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% KOH solution
Number of subjects: 26
Study 22214282 — intervention group
Group type: COMPARATOR
Intervention: SAL + LAC combination
Number of subjects: 26
Study 21632288 — intervention group
Group type: EXPERIMENTAL
Intervention: PANCREAZE® (pancrelipase)
Number of subjects: 49
Study 21632288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 18060837 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise (physiotherapy-supervised, moderate intensity walking program)
Number of subjects: 93
Study 18060837 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking/breathing exercise (same walking program plus musculoskeletal and respiratory exercises)
Number of subjects: 93
Study 18060837 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention (gentle mobilisation)
Number of subjects: 93
Study 18060837 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise and Walking/breathing exercise
Number of subjects: 93
Study 17074239 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative placement of collagen pieces within the parotid bed during parotidectomy
Number of subjects: 100
Study 17074239 — intervention group
Group type: COMPARATOR
Intervention: Conventional parotidectomy without collagen pieces
Number of subjects: 100
Study 14765001 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic gamblers
Number of subjects: 40
Study 14765001 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalogram (EEG) results in gamblers
Number of subjects: 40
Study 14765001 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 10830201 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular red cell transfusions (sufficient to reduce the percentage of Hb S gene product from over 90 to less than 30 of total hemoglobin)
Number of subjects: 130
Study 10830201 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 130
Study 10168261 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued intervention
Number of subjects: 0
Study 10168261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapsed intervention
Number of subjects: 0
Study 10168261 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed intervention
Number of subjects: 0
Study 10168261 — intervention group
Group type: COMPARATOR
Intervention: Continued control
Number of subjects: 0
Study 31521062 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 13
Study 31521062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31521062 — intervention group
Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 13
Study 29796866 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone (1 cc)
Number of subjects: 62
Study 29796866 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cc (15 μg/ml) oxygen‐ozone (O2‐O3)
Number of subjects: 62
Study 29796866 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study 26289496 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure activity program (30 min/3 times/week for 24 weeks)
Number of subjects: 42
Study 26289496 — intervention group
Group type: COMPARATOR
Intervention: Normal care activities (Control)
Number of subjects: 42
Study 24799100 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride and epinephrine at 1:100,000 (Alphacaine; DFL, Brazil)
Number of subjects: 25
Study 22950711 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (90 mg/d)
Number of subjects: 656
Study 22950711 — intervention group
Group type: COMPARATOR
Intervention: Placebo (90 mg/d)
Number of subjects: 656
Study 19855334 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal exercises 3 days per week
Number of subjects: 71
Study 19855334 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal exercises 6 days per week
Number of subjects: 71
Study 19855334 — intervention group
Group type: COMPARATOR
Intervention: No abdominal exercises (0 days per week)
Number of subjects: 71
Study 16368883 — intervention group
Group type: EXPERIMENTAL
Intervention: Large FLT3/ITDs (> or = 40 nucleotides)
Number of subjects: 151
Study 16368883 — intervention group
Group type: EXPERIMENTAL
Intervention: Small FLT3/ITDs (< 40 nucleotides)
Number of subjects: 151
Study 16368883 — intervention group
Group type: EXPERIMENTAL
Intervention: No FLT3/ITDs
Number of subjects: 151